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β1-adrenergic receptor 
O-glycosylation regulates 
N-terminal cleavage and signaling 
responses in cardiomyocytes
Misun Park1, Gopireddy R. Reddy2, Gerd Wallukat3, Yang K. Xiang  2,4 & Susan F. Steinberg1
β1-adrenergic receptors (β1ARs) mediate catecholamine actions in cardiomyocytes by coupling to both 
Gs/cAMP-dependent and Gs-independent/growth-regulatory pathways. Structural studies of the β1AR 
define ligand-binding sites in the transmembrane helices and effector docking sites at the intracellular 
surface of the β1AR, but the extracellular N-terminus, which is a target for post-translational 
modifications, typically is ignored. This study identifies β1AR N-terminal O-glycosylation at Ser37/Ser41  
as a mechanism that prevents β1AR N-terminal cleavage. We used an adenoviral overexpression 
strategy to show that both full-length/glycosylated β1ARs and N-terminally truncated glycosylation-
defective β1ARs couple to cAMP and ERK-MAPK signaling pathways in cardiomyocytes. However, 
a glycosylation defect that results in N-terminal truncation stabilizes β1ARs in a conformation that 
is biased toward the cAMP pathway. The identification of O-glycosylation and N-terminal cleavage 
as novel structural determinants of β1AR responsiveness in cardiomyocytes could be exploited for 
therapeutic advantage.
β1-adrenergic receptors (β1ARs) are the principle mediators of catecholamine actions in cardiomyocytes. β1ARs 
rapidly adjust cardiac output by activating a Gs-adenylyl cyclase (AC) pathway that increases cAMP, activates 
protein kinase A (PKA), and phosphorylates substrates involved in excitation-contraction coupling. While β1ARs 
can also activate cardioprotective Gs-independent mechanisms via the recruitment of β-arrestin and transactiva-
tion of an epidermal growth factor receptor (EGFR) pathway that activates ERK1, chronic β1AR activation leads 
to a spectrum of changes (including cardiomyocyte hypertrophy/apoptosis, interstitial fibrosis, and contractile 
dysfunction) that contribute to the evolution of heart failure (HF)2, 3. βAR inhibitors that prevent maladaptive 
cAMP-driven βAR responses have become standard therapy for HF.
βARs have provided a useful prototype for structural and NMR spectroscopic studies designed to elucidate the 
molecular dynamics of G protein-coupled receptor (GPCR) activation4–6. However, studies to date have focused 
primarily on the human β2AR, the first hormone-activated GPCR to be cloned and structurally characterized5, 6. 
While β1- and β2ARs share considerable sequence homology in the transmembrane regions that form their 
ligand-binding pockets, other regions of these receptors are more divergent. In particular, the β1- and β2AR extra-
cellular N-termini show no sequence homology. Since the βAR N-terminus has traditionally been viewed as 
having a negligible role in mechanisms that contribute to receptor activation and regulation, these relatively short 
and highly dynamic regions of the receptor generally are removed for structural studies. However, the notion that 
the βAR N-terminus can be dismissed as functionally unimportant is at odds with the fact that non-synonymous 
single nucleotide polymorphisms (SNPs) localized to the N-terminal regions of both the β1 and β2AR function as 
genetic determinants of βAR inhibitor responses and clinical outcome in HF7.
β1 and β2AR N-termini also are targets for sugar-based modifications (i.e., glycosylation). Protein glycosyl-
ation is an abundant post-translational modification that functions to expand the diversity of the proteome. 
Glycosylation is subdivided into two major categories (N- or O-glycosylation) based upon the residue within the 
protein backbone that serves as an attachment site for the branched sugar polymer (or glycan). N-glycosylation 
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is initiated in the endoplasmic reticulum by the actions of an oligosaccharide transferase which catalyzes the en 
bloc transfer of a preformed complex glycan structure to the amide nitrogen on the side chain of an asparagine 
residue (in a Asn-x-Ser/Thr consensus sequence - where x is any residue other than proline8). The N-linked 
glycan structure then undergoes extensive modification during protein transport from the Golgi to the plasma 
membrane. In contrast, O-glycosylation is initiated by the transfer a single monosaccharide (generally α-GalNAc) 
to the hydroxyl group of an acceptor serine or threonine residue8, 9. This reaction (which is catalyzed by a pol-
ypeptide GalNAc-transferase, a multi-gene family of ~20 different enzymes) is then followed by the step-wise 
enzymatic transfer of additional sugars (including galactose, GlcNac, and fucose) to yield a spectrum of higher 
order linear and branched glycan structures. Both N- and O-linked glycan structures are then typically capped 
with negatively charged sialic acids. Glycan structures (in some cases on specific proteins) have been implicated 
in a vast number of key biological processes (including protein trafficking to membranes, cell adhesion, signal 
transduction, endocytosis) that are critical for normal embryonic development and normal organ physiology8. 
Recent studies also indicate that glycan structures are highly regulated during developmental and in response 
to environmental stimuli (conditions that leads to changes in the relative abundance and location of individual 
glycosyltransferase enzymes, the abundance and trafficking of glycoprotein substrates, and/or the availability of 
activated sugar donors) and that disordered protein glycosylation is a common feature of various inflammatory 
and metabolic disorders and a hallmark of certain cancers10, 11.
βARs have both been categorized as glycoproteins, but the number and types of glycan attachments to the 
β1AR versus the β2AR are quite different. The β2AR contains 2 sites for N-linked glycosylation at its extreme 
N-terminus (at N6GSAFLLAPN15GS)12. β2AR N-glycosylation has been implicated as a mechanism that influ-
ences β2AR trafficking to cell surface membranes; it does not influence β2AR ligand binding or coupling to the 
Gs-cAMP pathway12. In contrast, the β1AR N-terminus contains a single site for N-linked glycosylation at Asn15 13. 
β1AR N-glycosylation at this site is reported to influence β1AR homodimerization and β1AR heterodimerization 
with α2ARs; effects on ligand binding or agonist-induced internalization are not detected14, 15. However, the β1AR 
N-terminus also is the target for O-linked glycosylation13. Computational algorithms have been used to map this 
modification to a cluster of consensus O-glycosylation sites (i.e., Ser in a Pro-rich region) at S37, S41, S47, and S49 
(Fig. 1)13, but the specific sites within the β1AR N-terminus that are targets for O-linked glycan modifications have 
never been unambiguously identified. This omission is pertinent, since Ser37, Ser41, and Ser47 are highly conserved 
in mammalian β1ARs, but sequence variation within the coding sequence of ADRB1 gives rise to the Gly49 allele 
in ~20% of Caucasian and ~15% of African Americans16. The notion that a Ser49Gly polymorphism might alter 
β1AR O-glycosylation patterns and thereby underlie this human SNP’s function as a clinically important mod-
ifier of βAR inhibitor responsiveness and outcome in patients with HF16 has never been considered. Similarly, 
Figure 1. Schematic of the 2-dimensional topology of the human β1AR. The single N-glycosylation site in 
the N-terminus at position 15, in a consensus sequence [Nx(S/T)] is shown in blue. Putative O-glycosylation 
consensus sites (Ser residues in a Pro-rich environment) examined in this study are shown in red; the Ser49Gly 
polymorphism maps to a putative O-glycosylation site. Cleavage sites previously identified at the β1AR 
N-terminus are shown in turquoise13; cleavage at P52-L53 generates a non-glycosylated receptor. Constructs 
used for the experiments depicted in Figs 2, 3 and 6 contained N-terminal FLAG (DYKDDDDK) and 
C-terminal HA (YPYDVPDYA) tags.
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the consequences of β1ARs O-glycosylation remain uncertain. There is evidence that clusters of O-glycans in 
other membrane-bound proteins alter protein secondary structure, serve as ligands for cell adhesion, and can 
be sources of antigen for the immune system17. Mucin-like O-glycans also have been implicated as barriers that 
prevent protein cleavage by proteases17, a property that might be particularly relevant the β1AR since the human 
β1AR (like its turkey counterpart) undergoes N-terminal cleavage at sites adjacent to the putative O-glycosylation 
sites (Fig. 1 and refs 13 and 18). This study uses molecular and biochemical strategies to map O-glycosylation sites 
on the β1AR N-terminus and show that O-glycosylation regulates β1AR cleavage, a process that in turn influences 
β1AR signaling properties in cardiomyocytes.
Results
β1AR Glycosylation Sites. β1AR glycosylation patterns were interrogated in Chinese hamster ovary (CHO) 
ldlD cells, a cell line that is UDP-galactose/UDP-N-acetylgalactosamine 4-epimerase-deficient. ldlD cells cannot 
synthesize UDP-Gal or UDP-GalNAc, the nucleotide sugars required for the addition of galactose (Gal) and 
N-acetylgalactosamine (GalNAc) to N- or O-linked oligosaccharides on glycoproteins, under conventional cul-
ture conditions with glucose as the sole sugar source19. However, the 4-epimerase defect can be bypassed and 
oligosaccharide synthesis can be fully restored by the addition of Gal and GalNAc to the culture medium, making 
ldlD cells a unique resource to map β1AR glycosylation sites.
Initial studies examined the expression patterns for WT-Ser49-β1ARs and WT-Gly49-β1ARs (the two β1AR pol-
ymorphic variants, see Fig. 1) in ldlD cells grown without or with Gal/GalNAc. Figure 2 shows that in the absence 
of Gal/GalNAc, both β1AR variants accumulate primarily as cleaved ~48–52-kDa species that are recognized by 
anti-β1AR and anti-HA (antibodies directed against C-terminal epitopes), but not by anti-Flag (which recognizes 
the N-terminal epitope tag). The very small amounts of a somewhat larger β1AR species that is produced under 
these conditions (and is detected by both anti-β1AR and anti-Flag) is presumed to represent a partially glyco-
sylated species that is produced as a result of a low level of sugar scavenging from serum glycoproteins20. Addition 
of Gal/GalNAc to the culture medium leads to the accumulation of two larger β1AR species; a full-length ~69-kDa 
β1AR that retains both N-terminal Flag and C-terminal HA tags and a smaller truncated form of the receptor that 
Figure 2. The S49G polymorphic variant does not grossly influence β1AR glycosylation profiles in ldlD cells. 
Lysates from ldlD cells transiently transfected with plasmids that drive expression of either S49- or G49-β1ARs 
and cultured without or with Gal (20 μM) and GalNAc (200 μM) were subjected to immunoblot analysis with 
two different anti-β1AR antibodies as well as antibodies to Flag and HA epitope tags at the N- and C-termini, 
respectively. The figure shows that the Abcam anti-β1AR antibody (ab3442, raised against residues 394–408 in 
human β1ARs) and the Santa Cruz anti-β1AR antibody (raised against some undefined C-terminal epitope) 
both detect the heterologously overexpressed β1AR. However, immunoblots with the Santa Cruz anti-β1AR 
antibody also contain some non-specific immunoreactivity. In particular, a ~69-kDa non-specific band that co-
migrates with the full-length, fully glycosylated β1AR can become rather problematic at low levels of transgene 
expression. Therefore, the Abcam reagent (which is more sensitive and specific) was used in subsequent 
experiments.
www.nature.com/scientificreports/
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lacks the N-terminal Flag tag. The migration of the ~69-kDa full-length β1AR is considerably slower than pre-
dicted from the calculated molecular weight of a full-length unglycosylated epitope-tagged receptor (~55-kDa) 
suggesting that the protein contains N- and/or O-linked glycans. Studies with Ser49- and Gly49-β1AR variants 
yielded similar results, indicating that β1AR glycosylation patterns are not grossly influenced by the S49G poly-
morphism. It is important to note that anti-β1AR antibodies from two different commercial sources (Abcam 3442 
and Santa Cruz sc-568) replicated the results with anti-HA; anti-β1AR and anti-HA antibodies detected bands 
with identical mobilities in transfected (but not non-transfected) cells under all experimental conditions. These 
results effectively address recent concerns regarding the specificity of the antibodies used to detect GPCRs such 
as the βAR21, 22 and indicate that these bands represent bona fide transgene products.
The observation that β1ARs accumulate in ldlD cells as full-length proteins only in the presence of Gal/GalNAc 
indicates that glycosylation in some way prevents β1AR cleavage. This could suggest a role for N- or O-linked sug-
ars on the β1AR itself, but a mechanism involving other cellular glycoconjugates is not excluded. Therefore, we 
mapped β1AR glycosylation sites and determined whether β1ARs glycosylation prevents β1AR cleavage.
We first used biochemical and mutagenesis approaches to identify β1AR species that contain N-linked glycans. 
Figures 3A and B show that the mobility of the major ~69-kDa species recognized by the anti-β1AR and anti-Flag 
antibodies increases when β1ARs are synthesized in the presence of tunicamycin (which prevents N-linked chain 
additions) or treated with PNGase F (which specifically hydrolyzes N-linked sugars); these results indicate that 
the ~69-kDa band contains N-linked glycans. The smaller ~55-kDa band detected by the anti-β1AR antibody 
(but not anti-Flag) is not influenced by tunicamycin or PNGF, indicating that this is an N-terminally cleaved 
species and that cleavage occurs C-terminal to the N-glycosylation site. Figure 3 shows that N15A-β1AR is 
detected as N-terminally truncated ~48- and 52-kDa species in ldlD cells cultured without Gal/GalNAc and that 
β1AR-N15A accumulates as two larger species in the presence of Gal/GalNAc: [1] a full length ~66-kDa species 
that is recognized by both anti-β1AR and anti-Flag antibodies - that has an electrophoretic mobility identical to 
WT-β1AR treated with tunicamycin or PNGF - and [2] a truncated ~55-kDa species that is selectively recognized 
by anti-β1AR, but not anti-Flag. β1AR-N15A is not influenced by tunicamycin or PNGF treatment. These results 
indicate that β1ARs contain a single site for N-glycosylation at position 15, that N-glycosylation is not required 
for full length β1AR expression, and that N-glycosylation does not grossly regulate β1AR N-terminal cleavage.
The observation that a N15A substitution prevents β1AR N-glycosylation, but does not discernibly alter β1AR 
processing/maturation provided the rationale to use the N-glycosylation-defective N15A-β1AR construct as 
a backbone for subsequent studies designed to identify sites for O-glycosylation. We focused on a cluster of 
Figure 3. Mutagenesis studies to map β1AR N-terminal glycosylation sites. ldlD cells transfected with wild 
type or single residue substituted forms of the β1AR were cultured without or with Gal (20 μM) and GalNAc 
(200 μM) as indicated. Tunicamycin (Tuni) was added to the culture medium (1 μg/ml for 24 hr) to block 
N-glycosylation in Panel A. Samples were incubated with PNGase F (PNGF 2 U/mL, 16 hr) to hydrolyze 
N-linked sugars in Panel B. Lysates were subjected to immunoblot analysis with an anti-β1AR antibody (raised 
against a β1AR C-tail epitope) or antibodies to Flag and HA epitope tags at the N- and C-termini, respectively. 
Positions of the full-length fully N- and O-glycosylated β1AR (filled triangle), the full-length O-glycosylated 
receptor (that lacks the N15-linked glycan, open triangle) and the N-terminally-cleaved unglycosylated receptors 
(asterisk) are indicated.
www.nature.com/scientificreports/
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consensus O-glycosylation sites at the juxtamembrane region of β1AR N-terminus, introducing S-A substitutions 
at positions 37, 41, and 47 into either Ser49-N15A-β1AR or Gly49-N15A-β1AR backbones.
Figure 3C shows that the introduction of a single S47A substitution into either in the Ser49-N15A-β1AR or 
Gly49-N15A-β1AR background does not alter the relative abundance or the mobility of the β1AR species that 
accumulate in ldlD cells cultured without or with Gal/GalNAc. These results effectively exclude Ser47 and Ser49 as 
a β1AR O-glycosylation sites or sites that regulate β1AR cleavage. Rather, Fig. 3C shows that β1AR mutants that 
harbor additional S-A substitutions at positions 37 and 41 (the Ser49-N15A-3SA-β1AR or Gly49-N15A-3SA-β1AR 
constructs) accumulate as an N-terminally cleaved ~48-kDa species (detected by anti-β1AR and anti-HA, but 
not anti-Flag) in ldlD cells incubation either without or with Gal/GalNAc. These results effectively map β1AR 
O-glycosylation sites to Ser37 and/or Ser41 and implicate O-glycosylation at these sites as a modification that pre-
vents β1AR N-terminal cleavage.
O-glycosylation was assessed further with neuraminidase (which removes terminal sialic acids from N- and 
O-linked sugars) and O-glycosidase (which removes O-linked glycan cores from glycoproteins only after the 
terminal sialic acid has been removed by neuraminidase). Figure 4 shows that neuraminidase treatment increases 
the electrophoretic mobility of N15A-β1ARs. Since the N15A substitution prevents β1AR N-glycosylation, these 
results indicate that β1ARs contain sialylated O-linked glycans. Treatment with O-glycosidase alone does not 
alter N15A-β1AR mobility, but the full-length ~65-kDa Ser49-N15A-β1AR species collapses to a ~55-kDa spe-
cies following combined treatment with O-glycosidase + neuraminidase. Deglycosylation experiments per-
formed in parallel on N15A-3SA-β1ARs and showed that the N15A-3SA-β1AR species that accumulates in Gal/
GalNAc-treated ldlD cells is not influenced by O-glycosidase and/or neuraminidase treatments (i.e., this species 
is neither sialylated nor O-glycosylated). Deglycosylation experiments on the Gly49 variant of the β1AR harbor-
ing N15A or N15A-3SA-β1AR yielded identical results (data not shown). Collectively, these results indicate that 
β1ARs accumulate as O-glycosylated species in ldlD cells cultured with Gal/GalNAc, that O-glycosylation sites 
also are heavily sialylated, and that O-linked sugar modifications at Ser37 and/or Ser41 prevent β1AR cleavage.
Finally, these experimental protocols were replicated using an untagged β1AR construct to address the possi-
ble concern that the epitope tags might influence β1AR maturation/glycosylation. These additional studies were 
considered important since a C-terminal tag on the β2AR subtype (which like the β1AR, terminates in a S-x-φ 
class I PDZ binding motif) disrupts PDZ domain-mediated protein interactions and prevents β2AR recycling 
to surface membranes following agonist-induced internalization23; N-terminal tags on βAR subtypes typically 
are viewed as functionally silent. Figure S1A shows that an untagged β1AR construct is detected as a ~69-kDa 
band, corresponding to the full-length β1AR, in ldlD cells grown with (but not without) Gal/GalNAc. Figure S1B 
shows that the electrophoretic mobility of this ~69-kDa band increases in response to treatment with PNGase F 
Figure 4. β1ARs carry sialylated N- and O-linked glycans that are released by enzymatic deglycosylation. 
Panel A: Schematics showing cleavage sites in representative N- or O-linked glycan structures. Enzymatic 
deglycosylations were performed with Neuraminidase (Neu), O-Glycosidase (O-Gly), and Peptide-N-
glycosidase F (PNGase F). Panel B: Lysates from ldlD cells transfected with S49-β1AR, S49-β1AR-N15A, or S49-
β1AR-N15A-3SA cultured without or with Gal (20 μM) and GalNAc (200 μM) were subjected to deglycosylation 
protocols as described in Methods. Lysates were then probed with antibodies that recognize C-terminal 
epitopes (anti-β1AR and anti-HA) or N-terminal Flag. Positions of the full-length fully N- and O-glycosylated 
β1AR (filled triangle), the full-length O-glycosylated receptor (that lacks the N15-linked glycan, open triangle), 
the full-length deglycosylated receptor (star), and the N-terminally-cleaved unglycosylated receptors (asterisk) 
are indicated.
www.nature.com/scientificreports/
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(indicating that it contains N-linked glycans) and that neuraminidase and O-glycosidase treatments produce fur-
ther increases in this band’s electrophoretic mobility over that produced by PNGase F treatment alone (indicating 
that it also contains sialylated O-linked glycans). The observation that the untagged β1AR is processed (like the 
tagged β1AR) to a ~69-kDa protein that contains sialylated N- and O-linked glycans in ldlD cells grown with Gal/
GalNAc establishes that the N- and C-terminal tags do not influence β1AR glycosylation.
β1ARs accumulate as both full-length and N-terminally cleaved species in cardiomyo-
cytes. We previously identified distinct molecular forms of the β1AR in rat cardiomyocyte cultures and rat 
ventricle and concluded that these distinct molecular species represent bona fide β1AR gene products, since sim-
ilar molecular heterogeneity of β1ARs is detected in the hearts of wild type mice but not β1AR null mutants24, 25. 
However, the previous immunoblotting studies relied exclusively on antibodies directed against C-terminal 
epitopes and could not resolve β1AR mobility differences due to receptor cleavage versus other mechanisms (for 
example, differential glycosylation or oxidative modifications at extracellular loop cysteines that influence intra-
molecular disulfide bond formation)26. Therefore, adenoviral-mediated gene transfer was used to overexpress 
N-terminally HA-tagged β1ARs in cardiomyocytes. Figure 5A shows that an antibody directed against a β1AR 
C-terminal epitope detects the transgene as both a larger ~69-kDa and two smaller ~45–50-kDa species and that 
only the larger ~69-kDa species carries the N-terminal HA-tag. These results indicate that the smaller species is 
the product of N-terminal cleavage in cardiomyocytes. Figure 5A also shows that both full-length and truncated 
forms of the β1AR are detected within 24 hr of adenoviral infection and their levels remain stable for up to 3 days.
Recent studies identify atrial-ventricular differences in glycosylation-associated gene (glycogene) expression 
that lead to chamber-specific differences in protein glycosylation27. Therefore, we performed immunoblotting as 
a general screen to identify tissue-specific difference in β1AR processing. Figure 5B shows that β1ARs are detected 
as a ~69-kDa species in membranes prepared from rat left ventricle and atrium and that atrium is relatively 
enriched in a smaller ~52-kDa species that co-migrates with the N-terminally truncated β1AR.
N-terminal truncation alters β1AR signaling in cardiomyocytes. We generated an N-terminally 
truncated form of the β1AR based upon a cleavage site identified by N-terminal sequencing in a previous study13 
and packaged this construct into an adenoviral vector to drive β1AR expression in cardiomyocytes. Untagged 
β1AR constructs were packaged into adenoviral vectors for these expression studies, to avoid any possible con-
founding effects of the epitope tags. Preliminary radioligand binding experiments established that membranes 
with similar levels of either full length (FL) or N-terminally truncated β1AR (Δ2-52-β1AR) immunoreactivity 
contain similar numbers of [125I]CYP binding sites (838 ± 91 vs. 725 ± 62 fmol/mg; n = 4, NS) that bind [125I]CYP 
with similar affinity (65.5 ± 29.4 vs. 77.5 ± 15.7 pM; n = 4, NS). The observation that an N-terminal truncation 
does not impair β1AR interactions with an antagonist ligand is consistent with structural studies that map the 
β1AR ligand binding pocket to residues in transmembrane helices and the second extracellular loop28.
Cardiomyocytes that heterologously overexpress similar levels of FL or N-terminally truncated β1ARs were 
challenged with a range of isoproterenol concentrations to determine whether N-terminal cleavage alters β1AR 
signaling to Gs/cAMP versus ERK pathways. Figure 6 shows that Ad-Δ2-52-β1AR cultures display a higher level 
of cAMP accumulation (and reduced ERK phosphorylation) in response to a range of isoproterenol concentra-
tions, compared to Ad-FL-β1AR cultures. While a previous study identified higher levels of the cleaved β1AR 
species following long-term (6 hr) agonist activation (and concluded that β1ARs are cleaved upon agonist activa-
tion13), the more short term isoproterenol treatment used in this study does not alter the abundance of any β1AR 
species in cardiomyocytes. These results argue that the N-terminal cleavage that is detected in cardiomyocytes is 
a stable modification that is completed prior to the delivery of the β1AR to the cell surface membrane and is not 
Figure 5. β1AR are detected as full-length and truncated species in cardiomyocytes. Panel A: Adenoviral-
mediated gene delivery was used to overexpress N-terminally tagged β1ARs in neonatal rat cardiomyocyte 
cultures. Lysates were prepared at 1–3 days following infection and probed for β1ARs, with β-actin used as a 
protein loading control. Panel B: Lysates prepared from adult left ventricular (LV) or atrial tissues were probed 
for β1AR expression (with ERK protein serving as loading control, since the anti-β-actin antibody - which gives 
a very robust signal in various cell culture preparations - performed poorly in lysates prepared from intact rat 
hearts). A shorter exposure of the β1AR immunoblot is included as Fig. S2.
www.nature.com/scientificreports/
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dynamically regulated by agonist activation. Rather, our studies indicate that N-terminal cleavage functions to 
alter the balance of β1AR signaling to the Gs/cAMP versus the ERK signaling pathway.
β1AR glycosylation influences responses to agonistic autoantibodies. Autoantibodies against the 
2nd extracellular loop of the β1AR accumulate in certain heart failure syndromes (Chagas’ disease, dilated car-
diomyopathy, ischemic cardiomyopathy) and contribute to the pathogenesis of these disorders by binding and 
activating the β1AR. We examined whether post-translational processing events localized to the β1AR N-terminus 
influence the β1AR responsiveness to anti-β1AR agonistic autoantibodies (AABs). The studies took advantage of 
membrane-targeted A-Kinase Activity Reporter (AKAR), a FRET reporter that senses plasma membrane local-
ized PKA activity29 (a localized signal that is regulated by a local pool of cAMP and may not necessarily track the 
global change in cAMP accumulation detected in Fig. 6). Figure 7 shows that both isoproterenol and anti-β1AR 
AABs increase plasma membrane PKA activity in cells that express WT-β1AR and glycosylation-defective 
β1AR-N15A-3SA. While the isoproterenol-dependent increase in membrane PKA activity is more robust at early 
time points (2–4 min) in WT-β1AR cells compared to β1AR-N15A-3SA cells, this difference wanes with more pro-
longed incubations. However, at all time points, the glycosylation-defective β1AR-N15A-3SA elicits a markedly 
exaggerated response to agonistic anti-β1AR AABs compared to WT-β1ARs. It’s worth noting that the AABs were 
better than isoproterenol at stabilizing β1AR-N15A-3SA in a conformation that activates membrane-localized 
PKA; a similar superior efficacy of some AABs batches - compared to isoproterenol - has been reported by others 
(although the notion that AABs might be particularly efficacious at only certain molecular forms of the β1ARs 
was not previously considered)30. These results support the conclusion that β1ARs are stabilized in a conformation 
that is biased toward the cAMP pathway as a result of defective O-glycosylation and/or the resultant N-terminal 
truncation.
Figure 6. N-terminal truncation influences β1AR signaling to cAMP versus ERK pathways in cardiomyocytes. 
Neonatal cardiomyocyte cultures were infected with empty vector (E) or adenoviruses that drive expression of 
FL (Ad-FL-β1AR) or truncated (Ad-∆2-52-β1AR) forms of the β1AR. Panel A: Cultures were preincubated with 
10 mM theophylline for 1 h at 37 °C and then challenged with vehicle or a range of isoproterenol concentrations 
and cAMP accumulation was measured according to Methods. Analysis by ANOVA followed by Tukey’s 
test showed that maximal cAMP accumulation is higher in Ad-∆2-52-β1AR than in Ad-FL-β1AR cultures 
(p < 0.05, n = 3). Panel B: Lysates from cultures treated for 5 min with vehicle or a range of isoproterenol 
concentrations were subjected to immunoblot analysis for ERK protein and phosphorylation and β1AR 
protein expression. Panel C: Quantification of pERK (normalized to ERK protein) in resting and 10−6 M 
isoproterenol-treated cultures infected with empty vector, FL-β1AR or ∆2-52-β1AR showing that basal pERK/
ERK ratios are not influenced by Ad-FL-β1AR or Ad-∆2-52-β1AR overexpression, but Isoproterenol-dependent 
ERK phosphorylation is higher in Ad-FL-β1AR than in Ad-∆2-52-β1AR cultures (mean ± SEM, n = 6, 
*p < 0.05). Panel D: FL-β1AR and ∆2-52-β1AR expression was quantified (by combining signals from the two 
immunoreactive species detected for each construct) and did not differ (mean ± SEM, n = 6, NS).
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Discussion
Protein O-glycosylation is an evolutionarily conserved mechanism that can enhance the functional diversity of 
a target protein. Most studies have focused on the dense clusters of GalNAc-type O-glycan modifications that 
decorate mucin-domains of relatively abundant secreted proteins that can be subjected to large-scale purifica-
tion for analytic methods. However, recent studies suggest that GalNAc-type O-glycosylation is a more common 
post-translational modification that also occurs at isolated sites on a wide range of proteins without mucin-like 
features. Progress toward identifying these other O-glycosylation sites (and in particular, the identification of 
O-glycosylation sites on cell surface proteins, such as G protein-coupled receptors) and efforts to understand 
the functional significance of O-glycan modifications in normal development and/or the pathogenesis of vari-
ous clinical disorders has lagged considerably at least in part due to several formidable technical challenges: [1] 
O-linked glycan structures are non-template driven modifications that characteristically shows high levels of 
structural diversity (‘microheterogeneity’), even at a single site within a given protein. [2] Pharmacologic com-
pounds that specifically inhibit polypeptide GalNAc transferases or enzymes that can be used to quantitatively 
release all O-glycan structures from protein backbones are not available. [3] The necessary and sufficient elements 
that comprise a consensus O-glycosylation motif remain uncertain; bioinformatics algorithms have been trained 
on a selective set of known O-glycoproteins and do not predict most sites identified in the human O-GalNAc 
glycoproteome using newly developed mass spectrometry methods31. [4] Available analytic techniques remain 
cumbersome and have substantial limitations. While there are isolated reports that O-glycan modifications dec-
orate the N-termini of certain G protein-coupled receptors (V2 vasopressin, LDL, and chemokine receptors32–34) 
and that O-linked sugars on the LDL receptor itself (rather than on other cellular components) prevent receptor 
N-terminal proteolytic cleavage and stabilize LDL receptors on the cell surface33, most studies of βARs have 
focused on the N-linked glycan modifications that can be detected on both β1AR and β2ARs. The O-glycan mod-
ifications that are confined to β1ARs are seldom considered. This study maps β1AR O-glycosylation sites and 
implicates O-glycosylation as a mechanism that prevents β1AR N-terminal cleavage and influences β1AR signal-
ing responses in cardiomyocytes.
We used a mutagenesis approach to show that β1AR O-glycosylation is confined to Ser37/Ser41 and does not 
involve Ser49, the site of a clinical relevant SNP35. This result is seemingly at odds with a previous report from 
the Liggett laboratory, which identified distinct electrophoretic mobilities for Ser49- and Gly49-β1ARs stably 
Figure 7. β1AR O-glycosylation influences responses to agonistic autoantibodies. Neonatal rat cardiomyocytes 
that heterologously overexpress PM-AKAR3 (the plasma membrane-localized PKA activity FRET biosensor) 
plus similar amounts of either S49-WT-β1AR or glycosylation defective S49-β1AR-N15A-3SA were stimulated 
with β1AR agonistic autoantibodies (AAB-loop2) or isoproterenol (10−7 M) and FRET was measured at 30 sec 
intervals. Note: The S49-WT-β1AR and S49-β1AR-N15A-3SA constructs used in these experiments are identical 
to the constructs used for the biochemical studies in Figs 2–4. Top: Time course for agonist-induced changes in 
FRET ratios (normalized to resting levels before drug). Bottom: Maximum FRET responses to AABs and Iso. 
*p < 0.01 by one-way ANOVA followed by Tukey’s test.
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overexpressed in clonal CHW lines and speculated that this difference reflects a indirect/long-range effect of 
the position 49 polymorphism to alter β1AR N-glycosylation at Asn15; a role for Ser49 O-glycosylation was not 
considered36. In fact, we obtained these clonal cell lines from the Liggett laboratory and replicated their findings; 
we believe that the distinct migration patterns for Ser49- and Gly49-β1ARs in the clonal cell lines generated in the 
Liggett laboratory can be attributed to the presence of some inopportune genetic alteration (at the level of the 
β1AR itself or some other protein that influences β1AR maturation/post-translational processing) in one of their 
clonal cells lines, since the electrophoretic mobilities of Ser49- and Gly49-β1ARs stably overexpressed in clonal lines 
generated in our laboratory or transiently overexpressed in a range of other cell types do not differ. Rather, our 
studies effectively exclude a role for Ser49 as a direct substrate for O-linked glycosylation or an indirect regulator 
of N-glycosylation.
We used a number of strategies to examine the functional consequences of β1AR O-glycosylation. First, we 
showed that O-glycosylation is required for full-length β1AR expression; β1ARs accumulate as N-terminally trun-
cated forms as a result of the O-glycosylation defect that results from Gal/GalNAc deprivation in ldlD cells or 
site-directed mutagenesis. There is precedent for this type of interplay between O-glycosylation and proteolytic 
cleavage, with site-specific O-glycosylation at juxtamembrane regions of certain other membrane proteins (in 
some cases regulated by specific ppGalNAc-T isoforms with tissue-restricted patterns of expression) conferring 
structural stability and protecting against proteolytic cleavage (i.e., preventing ectodomain shedding)37. The iden-
tification of an O-glycosylation/N-terminal cleavage mechanism that gives rise to distinct molecular forms of the 
β1AR provides the first credible explanation for the molecular heterogeneity displayed by native β1ARs in various 
cardiac preparations; the endogenous β1AR in cardiomyocyte cultures and mouse ventricle is detected as two 
distinct species, a larger ~69-kDa band (corresponding to the full-length/glycosylated receptor) and a smaller 
~50-kDa band (that co-migrates with the N-terminally truncated β1AR).
An O-glycosylation regulated event that regulates β1AR processing is predicted to have important functional 
implications since the cardiac glycome is extensively remodeled during normal ventricular developmental and in 
the setting of cardiac hypertrophy27, 38, 39. It is interesting to speculate that developmental- or disease-associated 
changes in the relative abundance of ppGalNAcT family enzymes that initiate O-glycosylation), the reper-
toire of glycosyltransferase enzymes that extend the core O-glycan structure (that produce diverse ensembles 
of branched glycan structures), or the expression of sialyltransferase enzymes that cap O- and N- linked gly-
cans with sialic acid might impact on β1AR glycosylation (and secondarily β1AR cleavage and β1AR respon-
siveness). The observation that glycan-modifying enzyme expression and protein glycosylation patterns are 
regulated in a tissue-specific manner (including between atrial versus ventricular tissues27) provides a likely 
explanation for the atrial-ventricular difference in the abundance of the smaller molecular form of the β1AR that 
co-migrates with N-terminally truncated β1ARs. Collectively, these results provide a strong rationale to consider 
functionally-important glycosylation-driven changes in β1AR structure as a dynamically regulated mechanism 
that contributes to the pathogenesis of various cardiac phenotypes. However, an analysis of site-specific glycan 
modifications on native β1ARs in various cardiac tissues (to characterize the structural changes in O-glycan moi-
eties that accompany or contribute to the pathogenesis of cardiac diseases) remains technically challenging even 
with the most contemporary O-glycoproteomic methods (see ref 40). More sophisticated analytic strategies that 
can be used to dissect glycan structural diversity, particularly on native O-glycoproteins in complex biological 
samples, are under development and will be critical for future progress in this area.
Our studies identify an O-glycosylation-regulated N-terminal cleavage event as a mechanism that alters β1AR 
signaling bias to cAMP/PKA versus ERK pathways. With the caveat that the functional studies were performed 
in overexpression models (and ultimately must be followed-up by studies that interrogate glycosylation/cleavage 
mechanisms that control the expression and action of native β1ARs at endogenous levels of β1AR expression), 
these studies suggest that an O-glycosylation-regulated mechanism that dictates β1AR responsiveness could 
underlie the cardiac phenotypes that develop in various syndromes associated with defective in glycoprotein gly-
cosylation. For example, congenital disorders of glycosylation due to mutations or deletion of genes that encode 
the enzymes that form the core O-glycan structures typically present with lethal ventricular arrhythmias and 
cardiomyopathies41. The molecular basis for this glycosylation-driven cardiac phenotype remains uncertain. 
Studies to date have linked defects in protein glycosylation (that disrupt protein sialylation) to changes in the 
gating properties of certain voltage-gated sodium and potassium channels, enhanced cardiac excitability, and 
increased susceptibility to ventricular arrhythmias27, 42–44. While changes in ion channel sialylation may contrib-
ute to the pathogenesis of the ventricular arrhythmias in these disorders, our studies provide a rationale to con-
sider whether defective β1AR O-glycosylation and the accumulation of an N-terminally truncated β1AR species 
that displays enhanced signaling to proarrhythmic cAMP/PKA responses also might contribute to this pathologic 
cardiac phenotype.
Ventricular arrhythmias also are a characteristic feature of acquired disorders of protein sialylation, such as 
Chagas disease. Trypanosoma cruzi (the causative agent of Chagas disease) releases a trans-sialidase that transfers 
sialic acid from glycoconjugates on the host cell to mucin-like proteins on the parasite cell surface. This results 
in changes in immune cell sialylation that effectively subvert some aspects of the host cell immune response45, 46. 
Of note, early studies linked Trypanosoma cruzi infection to changes in βAR responsiveness that in some cases 
correlate with the severity of chagasic cardiomyopathy47–49. The prevailing notion is that the disordered immune 
response leads to the generation of agonistic anti-β1AR autoantibodies that activate the cAMP signaling pathway 
and contribute to chagasic cardiomyopathy. While there is direct evidence that agonistic anti-β1AR autoanti-
body treatment results in a cardiomyopathic phenotype50, the limited correlation between circulating levels of 
anti-β1AR autoantibodies and the severity of cardiac dysfunction51 suggests that other mechanisms also may 
be contributory. Our studies provide the rationale to consider whether a Trypanosoma cruzi infection induced 
decrease in β1AR sialylation might facilitate β1AR N-terminal cleavage, enhance agonistic antibody-dependent 
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activation of the cAMP/PKA pathway (while dampening signaling via the cardioprotective ERK pathway), and 
promote adverse cardiac remodeling.
Finally, our studies identify the β1AR extracellular N-terminus as a heretofore unrecognized structural deter-
minant of β1AR responsiveness. The notion that a glycan-regulated event localized to the N-terminus can influ-
ence β1AR responsiveness represents a paradigm shift from previous research that focused almost exclusively 
on the ligand binding sites in transmembrane helices or effector docking sites in the intracellular loops and the 
C-terminus. However, our results resonate with a small but growing literature that link structural perturbations 
(and/or changes in glycosylation) localized to the N-terminus to altered GPCR cell surface expression or com-
partmentation to lipid raft microdomains, changes in the kinetics of ligand-induced internalization, changes in 
the efficiency of receptor dimerization, and altered signaling bias to downstream effectors14, 52, 53. The identifi-
cation of an O-glycan-regulated cleavage event that regulates β1AR signaling to cAMP/PKA vs ERK provides 
a strong rational for future studies that identify the O-glycan modifying enzymes and specific protease(s) that 
execute these post-translational modifications at the β1AR N-terminus and the specific role of glycan-mediated 
changes in β1AR structure/function in the pathogenesis of various cardiac disorders. The identification of 
O-glycosylation and/or receptor cleavage sites that are specific to the β1AR N-terminus, that add plasticity to 
catecholamine-dependent signaling responses, could represent promising novel targets for β1-subtype specific 
therapeutics.  
Note. While this manuscript was under revision, a publication from Goth et al. described the sites and func-
tional consequences of beta1-adrenergic receptor O-glycosylation (JBC 292:4714,2017).  We believe that meth-
odologic differences explain certain discrepancies between the findings in this recent publication and the results 
reported herein. First, Goth et al. used in vitro O-glycosylation assays with peptides based upon the β1-adrenergic 
receptor N-terminus and recombinantly expressed GalNAc-transferase 2 to identify O-glycosylation at Ser37/
Ser41 and Ser47/Ser49.  Our studies, which show that Ser47and Ser49 are not O-glycosylated in vivo in 
GalNAc-transferase 2-expressing ldlD-CHO cells, suggest that the in vitro approach is too promiscuous to 
be used as a surrogate to predict in vivo O-glycosylation sites on the full length β1-adrenergic receptor pro-
tein.  Second, Goth et al. linked an O-glycosylation defect to a decrease in Iso-dependent cAMP accumulation. 
However, this conclusion was based on studies in β1-adrenergic receptor-expressing GalNac-T2/T3 knock-out 
HEK293 cells and may be misleading, since this cell model has a generalized defect in O-glycosylation of 
β1-adrenergic receptors, adenylyl cyclase, and a wide array of other cellular proteins. Our studies show that the 
truncated/glycosylation-defective β1-adrenergic receptor couples to enhanced cAMP accumulation in cardiomy-
ocytes (a physiologically relevant cell type).
Materials and Methods
Materials. Antibodies were from the following sources: anti-β1AR (clone V-19, which was raised against 
a peptide that maps to the C-terminus of the mouse β1AR) and anti-HA (clone Y-11) were from Santa Cruz 
Biotechnology (Dallas, TX). Anti-β1AR (ab3442, raised against residues 394–408 in human β1-ARs) and anti-β-
actin were from Abcam (Cambridge, MA). Anti-Flag M2 antibody was from Sigma-Aldrich (Saint Louis, MO). 
Antibodies that recognize ERK protein and phosphorylation were from Cell Signaling Technology (Danvers, 
MA). Goat anti-rabbit and goat anti-mouse IgG (H + L)-Horse radish peroxidase conjugates were from Bio-
Rad Laboratories, Inc. (Hercules, CA). Peptide-N-glycosidase F (PNGF), O-glycosidase (O-Gly), neuraminidase 
(Neu), propranolol, isoproterenol (Iso), and tunicamycin were obtained from Sigma-Aldrich (Saint Louis, MO). 
All other chemicals were reagent grade.
Plasmids. A plasmid that drives expression of the human S49R389-β1AR harboring an N-terminal Flag-tag 
and C-terminal HA-tag was from Addgene. The various single residue substituted β1AR mutant constructs used 
in this study were generated using the QuikChange mutagenesis system (Agilent Technologies). A plasmid that 
drives expression of the N-terminally truncated human β1AR (GenBankTM accession number P08588) (∆2-
52-β1AR) harboring a C-terminal Flag tag was kindly provided by Dr. Ulla E. Petäjä-Repo from University of 
Oulu, Finland54. Adenoviruses that drive expression of the full-length and N-terminally truncated forms of the 
human β1AR (Ad-FL-β1AR and Ad-∆2-52-β1AR) were prepared by Welgen Inc. (Worcester, MA).
HEK293 and ldlD cell culture and transfection. HEK293 cells were cultured in DMEM (Gibco 
life technologies) containing 10% FBS, 100 units/ml penicillin-streptomycin, and 2mM L-glutamine. ldlD 
cells were cultured in DMEM/F-12 (Ham) (1:1) (Gibco life technologies) with 10% FBS and 100 units/ml 
penicillin-streptomycin either without or with Gal (20 μM) and GalNAc (200 μM). Cell transfections were per-
formed with the Effectene Transfection reagent (Qiagen) according to manufacturer’s instructions.
Neonatal Cardiomyocyte Culture and Adenoviral Infections. Cardiomyocytes were isolated from 
the hearts of 2-day-old Wistar rats and infected with adenoviral constructs that drive expression of full length or 
N-terminally truncated β1ARs according to methods published previously55, 56. All procedures were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (NIH Publication, 8th Edition, 2011) and were approved by the Columbia University Institutional Animal 
Care and Use Committee (protocol AC-AAAH6903).
Immunoblotting. Immunoblotting was performed on cell extracts according to methods described pre-
viously or manufacturer’s instructions55. The dilutions for primary and secondary antibodies were as follows: 
Abcam anti-β1AR (ab3442) at 1:3000 followed by secondary goat anti-rabbit IgG at 1:5000; Santa Cruz anti-β1AR 
(clone V-19) at 1:1000 followed by secondary goat anti-rabbit IgG at 1:2000; anti-HA (Y-11) at 1:3000 followed 
by secondary goat anti-rabbit IgG at 1:5000; anti-Flag M2 at 1:700 followed by secondary goat anti-mouse IgG at 
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1:1000; anti-pERK at 1:2000 followed by secondary goat anti-rabbit IgG at 1:3000; anti-ERK at 1:3000 followed 
by secondary goat anti-rabbit IgG at 1:5000; anti-β-actin at 1:2500 followed by secondary goat anti-mouse IgG at 
1:4000. Each panel in each figure represents the results from a single gel (exposed for a uniform duration); detec-
tion was with enhanced chemiluminescence or LI-COR Odyssey CLx imaging system (LI-COR Biosciences) with 
image Studio Lite Ver 5.0 software used for quantification of protein expression. All results were replicated in at 
least three experiments on separate culture preparations.
Enzymatic deglycosylation. Samples were deglycosylated by preincubation with peptide-N-glycosidase 
F (PNGase F), O-glycosidase (O-Gly), α-(2 → 3, 6, 8, 9)-neuraminidase (Sialidase A, Neu) for overnight at 37 °C 
using Enzymatic Protein Deglycosylation Kit (EDEGLY kit, Sigma) according to manufacturer’s instructions.
Measurements of βAR affinity and cAMP accumulation. Radioligand binding experiments with 
[125I]ICYP were performed on membrane preparations according to methods published previously57. cAMP 
accumulation was measured according to standard methods as described previously58. In brief, cells cultured in 
6-well plates, infected with adenoviral constructs, and then 3 days later preincubated with 10 mM theophylline 
for 60 min and challenged for 5 min with vehicle or Iso. Assays were terminated by aspiration of the incubation 
buffer and addition of 0.5 mL of 100% ice-cold ethanol to each well. Cell lysates were dried in a spin vacuum and 
cAMP in the residue was quantified with a commercially available cAMP enzyme-linked immunosorbent assay 
kit (R&D Systems, Minneapolis, MN) according to manufacturer’s instructions.
Fluorescent Resonance Energy Transfer (FRET) Measurements to track sarcolemmal PKA activ-
ity. Neonatal cardiomyocyte cultures were infected with PM-AKAR3 (a plasma membrane-targeted PKA 
activity reporter) according to methods described previously29. Images were acquired using a Leica DMI3000B 
inverted fluorescence microscope (Leica Biosystems, Buffalo Grove, IL) with a 40X oil-emersion objective lens 
and a charge-coupled device camera controlled by Metafluor software (Molecular Devices, Sunnyvale, CA). FRET 
was recorded by exciting the donor fluorophore at 430–455 nm and measuring emission fluorescence with two 
filters (475DF40 for cyan and 535DF25 for yellow). Images were subjected to background subtraction, and were 
acquired every 20 seconds with exposure time of 200 ms. The donor/acceptor FRET ratio was calculated and nor-
malized to the ratio value of baseline. The binding of cAMP to AKAR3 increases YFP/CFP FRET ratio59.
Statistics. Results are shown as mean ± SEM and were analyzed by Student’s t test or ANOVA for multiple 
comparisons, with P < 0.05 considered statistically significant.
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